dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: IL-2 receptor family (type: catalytic_receptor)
Target: Interleukin-7 receptor subunit &alpha;

Ligand: OSE-127 (Antibody)
Interaction type: Antibody
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 11.399999618530273 pEC50
Reference (Patent): Antibodies directed against CD127
Target family: IL-2 receptor family (type: catalytic_receptor)
Target: Interleukin-9 receptor

Ligand: IL-9 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-2 receptor family (type: catalytic_receptor)
Target: Thymic stromal lymphopoietin receptor

Ligand: thymic stromal lymphopoietin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-2 receptor family (type: catalytic_receptor)
Target: Interleukin-2 receptor

Ligand: Ro26-4550 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Identification of a small molecule inhibitor of the IL-2/IL-2R alpha receptor interaction which binds to IL-2.
Published in: J Am Chem Soc
Target family: IL-2 receptor family (type: catalytic_receptor)
Target: Interleukin-15 receptor

Ligand: ALT-803 (Antibody)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 12.300000190734863 pIC50
Reference (Journal): Novel human interleukin-15 agonists.
Published in: J Immunol

Ligand: ALT-803 (Antibody)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 10.8100004196167 pEC50
Reference (Journal): IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization.
Published in: Cytokine

Ligand: IL-15 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 11.420000076293945 pIC50
Reference (Journal): Novel human interleukin-15 agonists.
Published in: J Immunol
Target family: IL-2 receptor family (type: catalytic_receptor)
Target: Interleukin-15 receptor subunit &alpha;

Ligand: IL-15 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 11.420000076293945 pKd
Reference (Patent): Conjugates of an il-15 moiety and a polymer
Target family: IL-2 receptor family (type: catalytic_receptor)
Target: Interleukin-21 receptor

Ligand: IL-21 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-2 receptor family (type: catalytic_receptor)
Target: Interleukin-2 receptor

Ligand: AF12198 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  -
Reference (Journal): AF12198, a novel low molecular weight antagonist, selectively binds the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1.
Published in: J Biol Chem

Ligand: IL-1 receptor antagonist (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  -

Ligand: IL-2 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1992)
Median affinity:  -
Target family: IL-3 receptor family (type: catalytic_receptor)
Target: Interleukin-5 receptor

Ligand: IL-5 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-3 receptor family (type: catalytic_receptor)
Target: Interleukin 5 receptor, &alpha; subunit

Ligand: benralizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2017), EMA (2018)
Primary target: no
Median affinity: 8.670000076293945 pKd
Reference (Patent): Methods of reducing eosinophil levels.

Ligand: IL-5 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-3 receptor family (type: catalytic_receptor)
Target: GM-CSF receptor, &alpha; subunit

Ligand: GM-CSF (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: mavrilimumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 9.859999656677246 pIC50
Reference (Patent): Antibody molecule for human GM-CSF receptor alpha.
Target family: IL-3 receptor family (type: catalytic_receptor)
Target: Granulocyte macrophage colony-stimulating factor receptor

Ligand: G-CSF (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Median affinity:  -

Ligand: GM-CSF (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-3 receptor family (type: catalytic_receptor)
Target: Interleukin-3 receptor

Ligand: IL-3 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-3 receptor family (type: catalytic_receptor)
Target: Interleukin 3 receptor, &alpha; subunit

Ligand: IL-3 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-3 receptor family (type: catalytic_receptor)
Target: Interleukin-5 receptor

Ligand: YM90709 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  -
Reference (Journal): Characterization of YM-90709 as a novel antagonist which inhibits the binding of interleukin-5 to interleukin-5 receptor.
Published in: Int Immunopharmacol
Target family: IL-6 receptor family (type: catalytic_receptor)
Target: Leukemia inhibitory factor receptor

Ligand: LIF (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: oncostatin M (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-6 receptor family (type: catalytic_receptor)
Target: Oncostatin-M receptor

Ligand: oncostatin M (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-6 receptor family (type: catalytic_receptor)
Target: Ciliary neutrophic factor receptor

Ligand: ciliary neurotrophic factor (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: CRCF1/CLCF1 heterodimer (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-6 receptor family (type: catalytic_receptor)
Target: Interleukin-11 receptor

Ligand: IL-11 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: oprelvekin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1997)
Primary target: yes
Median affinity:  -
Reference (Journal): Preclinical pharmacologic basis for clinical use of rhIL-11 as an effective platelet-support agent.
Published in: Oncology (Williston Park, NY)

Ligand: oprelvekin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1997)
Primary target: yes
Median affinity:  -
Reference (Journal): Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia.
Published in: BioDrugs
Target family: IL-6 receptor family (type: catalytic_receptor)
Target: Interleukin-27 receptor

Ligand: IL-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-6 receptor family (type: catalytic_receptor)
Target: Interleukin-31 receptor

Ligand: IL-31 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-6 receptor family (type: catalytic_receptor)
Target: Interleukin-31 receptor, &alpha; subunit

Ligand: nemolizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: Japan (2022)
Primary target: yes
Median affinity: 8.699999809265137 pKd
Reference (Patent): Anti-NR10 antibody and use thereof.
Target family: IL-6 receptor family (type: catalytic_receptor)
Target: Interleukin-6 receptor

Ligand: IL-6 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity: 9.359999656677246 pKd
Reference (Journal): Structural and functional studies on the human interleukin-6 receptor. Binding, cross-linking, internalization, and degradation of interleukin-6 by fibroblasts transfected with human interleukin-6-receptor cDNA.
Published in: J Biol Chem

Ligand: satralizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: Canada, Japan and FDA (2020), EMA (2021)
Primary target: yes
Median affinity: 8.850000381469727 pKd
Reference (Patent): Antibody molecules that bind to IL-6 receptor.

Ligand: tocilizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: Japan (2005), EMA (2009), FDA (2010)
Primary target: yes
Median affinity: 8.600000381469727 pKd

Ligand: vobarilizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 12.720000267028809 pKd
Reference (Journal): The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.
Published in: Arthritis Res Ther
Target family: IL-6 receptor family (type: catalytic_receptor)
Target: Interleukin-6 receptor, &alpha; subunit

Ligand: IL-6 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity: 9.359999656677246 pKd
Reference (Journal): Structural and functional studies on the human interleukin-6 receptor. Binding, cross-linking, internalization, and degradation of interleukin-6 by fibroblasts transfected with human interleukin-6-receptor cDNA.
Published in: J Biol Chem

Ligand: sarilumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: EMA & FDA (2017)
Primary target: yes
Median affinity:  pKd
Reference (Patent): High affinity antibodies to human IL-6 receptor.
Target family: IL-6 receptor family (type: catalytic_receptor)
Target: Leptin receptor

Ligand: leptin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 10.1899995803833 pKd
Reference (Journal): Kinetics of leptin binding to the Q223R leptin receptor.
Published in: PLoS ONE
Target family: IL-6 receptor family (type: catalytic_receptor)
Target: Leukemia inhibitory factor receptor

Ligand: cardiotrophin-1 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: ILK subfamily (type: enzyme)
Target: integrin linked kinase

Ligand: compound 22 [PMID: 21823616] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.21999979019165 pIC50
Reference (Journal): Identification and characterization of a novel integrin-linked kinase inhibitor.
Published in: J Med Chem
Target family: Immune checkpoint catalytic receptors (type: catalytic_receptor)
Target: CD40

Ligand: CFZ533 (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 9.15999984741211 pKd
Reference (Patent): Silent fc variants of anti-cd40 antibodies.
Target family: Immune checkpoint catalytic receptors (type: catalytic_receptor)
Target: herpes virus entry mediator

Ligand: LIGHT (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -

Ligand: B and T lymphocyte attenuator (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -

Ligand: lymphotoxin-α (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Immune checkpoint catalytic receptors (type: catalytic_receptor)
Target: CD40

Ligand: CD40 ligand (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Immunoglobulin C1-set domain-containing proteins (type: other_protein)
Target: Fc fragment of IgG receptor and transporter

Ligand: rozanolixizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2023)
Primary target: no
Median affinity:  pKd
Reference (Patent): Anti-fcrn antibodies

Ligand: ziltivekimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 6.440000057220459 pKd
Reference (Journal): Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics.
Published in: J Mol Biol

Ligand: DX-2507 (Antibody)
Interaction type: Antibody
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 8.739999771118164 pKd
Reference (Journal): Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates.
Published in: Front Immunol

Ligand: efgartigimod alfa (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2021), EMA (2022)
Primary target: no
Median affinity:  -
Reference (Journal): Argx-113, a Novel Fc-Based Approach for Antibody-Induced Pathologies Such As Primary Immune Thrombocytopenia
Published in: Blood

Ligand: ziltivekimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 6.650000095367432 pKd
Reference (Journal): Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics.
Published in: J Mol Biol
Target family: Immunoglobulin C2-set domain-containing proteins (type: other_protein)
Target: nectin cell adhesion molecule 4

Ligand: enfortumab vedotin (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2019), EMA (2022)
Primary target: yes
Median affinity:  -
Reference (Journal): Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
Published in: Expert Opin Investig Drugs
Target family: Immunoglobulin C2-set domain-containing proteins (type: other_protein)
Target: melanoma cell adhesion molecule

Ligand: imaprelimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 8.0600004196167 pKd
Reference (Patent): Anti-mcam antibodies and associated methods of use
Target family: Immunoglobulin C2-set domain-containing proteins (type: other_protein)
Target: nectin cell adhesion molecule 4

Ligand: BT7480 (Peptide)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.289999961853027 pKd
Reference (Journal): Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology.
Published in: J Med Chem
Target family: Immunoglobulin like domain containing proteins (type: other_protein)
Target: advanced glycosylation end-product specific receptor

Ligand: azeliragon (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 6 pIC50
Reference (Patent): Rage antagonists as agents to reverse amyloidosis and diseases associated therewith.
Target family: Immunoglobulin like domain containing proteins (type: other_protein)
Target: MALT1 paracaspase

Ligand: JNJ-67856633 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.130000114440918 pIC50
Reference (Patent): Pyrazole derivatives as malt1 inhibitors

Ligand: compound 20c [PMID: 34181850] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.28000020980835 pIC50
Reference (Journal): Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.
Published in: J Med Chem
Target family: Immunoglobulin like domain containing proteins (type: other_protein)
Target: Fc fragment of IgG receptor IIIa

Ligand: bemarituzumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.039999961853027 pKd
Reference (Journal): Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial.
Published in: Cancer Chemother Pharmacol

Ligand: AFM13 (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity:  pKd
Reference (Journal): A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.
Published in: MAbs
Target family: Immunoglobulin like domain containing proteins (type: other_protein)
Target: Fc fragment of IgA receptor

Ligand: BsAb (CD89-CD20) (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 8.489999771118164 pKd
Reference (Journal): CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy.
Published in: Oncoimmunology
Target family: Immunoglobulin like domain containing proteins (type: other_protein)
Target: advanced glycosylation end-product specific receptor

Ligand: azeliragon (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 6 pIC50
Reference (Journal): New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy.
Published in: Front Aging Neurosci
Target family: Immunoglobulin like domain containing proteins (type: other_protein)
Target: MALT1 paracaspase

Ligand: SGR-1505 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Patent): Cyclic compounds and methods of using same

Ligand: safimaltib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.130000114440918 pIC50
Reference (Patent): Pyrazole derivatives as malt1 inhibitors

Ligand: pecazine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Primary target: no
Median affinity: 6.289999961853027 pIC50
Reference (Journal): Structural analysis of phenothiazine derivatives as allosteric inhibitors of the MALT1 paracaspase.
Published in: Angew Chem Int Ed Engl
Target family: Immunoglobulin-like family of IL-1 receptors (type: catalytic_receptor)
Target: Interleukin-36 receptor

Ligand: IL-36γ (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: IL-36β (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: IL-36α (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: Immunoglobulin-like family of IL-1 receptors (type: catalytic_receptor)
Target: Interleukin-33 receptor

Ligand: IL-33 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: Immunoglobulin-like family of IL-1 receptors (type: catalytic_receptor)
Target: Interleukin-1 receptor, type I

Ligand: isunakinra (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 10.520000457763672 pKd
Reference (Journal): Preclinical Development of EBI-005: An IL-1 Receptor-1 Inhibitor for the Topical Ocular Treatment of Ocular Surface Inflammatory Diseases.
Published in: Eye Contact Lens

Ligand: IL-1 receptor antagonist (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  -

Ligand: IL-1β (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: IL-1α (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: anakinra (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (no history prior to 2001), EMA (2002)
Primary target: yes
Median affinity: 7.820000171661377 pKd
Reference (Journal): Interleukin-1 receptor antagonist binds to the type II interleukin-1 receptor on B cells and neutrophils.
Published in: J Biol Chem
Target family: Immunoglobulin-like family of IL-1 receptors (type: catalytic_receptor)
Target: Interleukin-1 receptor-like 2

Ligand: spesolimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA and EMA (2022)
Primary target: no
Median affinity: 10.520000457763672 pKd
Reference (Patent): Anti IL-36R antibodies
Target family: Immunoglobulin-like family of IL-1 receptors (type: catalytic_receptor)
Target: Interleukin-1 receptor, type I

Ligand: AF12198 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  -
Reference (Journal): AF12198, a novel low molecular weight antagonist, selectively binds the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1.
Published in: J Biol Chem
Target family: Immunoglobulin-like family of IL-1 receptors (type: catalytic_receptor)
Target: Interleukin-1 receptor-like 2

Ligand: MAB92 (Antibody)
Interaction type: Antibody
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 10.619999885559082 pKd
Reference (Journal): Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies.
Published in: MAbs
Target family: Immunoglobulin-like family of IL-1 receptors (type: catalytic_receptor)
Target: Interleukin-18 receptor

Ligand: IL-37 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: IL-18 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: Immunoglobulin-like family of IL-1 receptors (type: catalytic_receptor)
Target: single Ig and TIR domain containing

Ligand: IL-37 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction.
Published in: Nat Immunol
Target family: Immunoglobulin-like family of IL-1 receptors (type: catalytic_receptor)
Target: Interleukin-36 receptor

Ligand: IL-36 receptor antagonist (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: Immunoglobulins (type: other_protein)
Target: immunoglobulin heavy constant epsilon

Ligand: omalizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2003), EMA (2005)
Primary target: yes
Median affinity: 7.590000152587891 pKd
Reference (Patent): Anti-IgE antibodies and methods of improving polypeptides.

Ligand: quilizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 8.819999694824219 pKd
Reference (Patent): Apoptotic anti-IgE antibodies

Ligand: ligelizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity:  pKd
Reference (Patent): High affinity anti-human IgE antibodies.

Ligand: ligelizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity:  pKd
Reference (Journal): Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects.
Published in: Clin Exp Allergy

Ligand: omalizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2003), EMA (2005)
Primary target: yes
Median affinity: 8.15999984741211 pKd
Reference (Journal): Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects.
Published in: Clin Exp Allergy